EP3604551A1 - COMPLEMENT-DEPENDENT CYTOTOXICITY AND SIALYLATION AS BIOMARKERS FOR PREDICTING CLINICAL RESPONSE TO CANCER TREATMENT WITH ANTIBODY OR DERIVATIVE MEDIATING COMPLEMENT ACTIVATION